Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. ANT
4. CDNS
5. META
6. BA
7. SPY
8. HOOD
9. INTC
10. JBLU

Go back to Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

August 10, 2015 4:30 PM EDT

CARMIEL, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE: PLX), today reported financial results for the second quarter of 2015.

"We recently reported positive Phase I results for PRX-106 (oral Anti-TNF), with exciting results showing biological activity in the gut and activation of regulatory T cells," said Moshe Manor, Protalix's President and Chief Executive Officer. "We look forward to selecting an indication and moving this program into a proof of concept trial around year-end. Additionally, we anticipate interim results for PRX-102 for the... More